Clinical trial

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in…

NCT00383162 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00383162
Title A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Official title A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Migraine Disorders
Intervention type Drug
Interventions Combination Product (sumatriptan succinate / naproxen sodium), Placebo
Enrollment 173
Start date Nov 1, 2006
Primary completion Oct 1, 2007
Completion Oct 1, 2007
First posted Oct 2, 2006
Last update posted Feb 2, 2017
Countries United States

At a glance

  • 10–99 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies